Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome

Näytä kaikki kuvailutiedot



Pysyväisosoite

http://hdl.handle.net/10138/313000

Lähdeviite

Holm , M , Joenväärä , S , Saraswat , M , Mustonen , H , Tohmola , T , Ristimäki , A , Renkonen , R & Haglund , C 2019 , ' Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome ' , FASEB BioAdvances , vol. 1 , no. 12 , pp. 723-730 . https://doi.org/10.1096/fba.2019-00062

Julkaisun nimi: Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome
Tekijä: Holm, Matilda; Joenväärä, Sakari; Saraswat, Mayank; Mustonen, Harri; Tohmola, Tiialotta; Ristimäki, Ari; Renkonen, Risto; Haglund, Caj
Muu tekijä: University of Helsinki, Department of Surgery
University of Helsinki, HUSLAB
University of Helsinki, HUSLAB
University of Helsinki, HUS Abdominal Center
University of Helsinki, HUSLAB
University of Helsinki, Department of Pathology
University of Helsinki, HUSLAB
University of Helsinki, HUS Abdominal Center
Päiväys: 2019-11-02
Kieli: eng
Sivumäärä: 8
Kuuluu julkaisusarjaan: FASEB BioAdvances
URI: http://hdl.handle.net/10138/313000
Tiivistelmä: Abstract Colorectal cancer (CRC) stands for 10% of the worldwide cancer burden and has recently become the second most common cause of cancer death. The 5-year survival rate depends mainly on stage at diagnosis. Mass spectrometric proteomic analysis is widely used to study the plasma proteome, which is complex and contains multitudes of proteins. In this study, we have used Ultra Performance Liquid Chromatography-Ultra Definition Mass Spectrometry (UPLC-UDMSE)-based proteomics to analyze plasma samples from 76 CRC patients. We identified several plasma proteins, such as CP, TVP23C, FETUB, and IGFBP3, of which altered levels led to significant differences in survival, as seen by Cox regression and Kaplan-Meier analysis. Additionally, during Cox regression analysis, samples were adjusted for age and/or tumor stage, enabling stringent analysis. These proteins, although in need of further validation, could be of use during patient follow-up, as their levels can non-invasively be measured from blood samples, and could be of use in predicting patient outcome. Several of these proteins additionally have roles in metabolism and inflammation, two processes central to the development and progression of cancer, further indicating their importance in cancer.
Avainsanat: mass spectrometry
outcome
plasma proteome
proteomics
stage
1182 Biochemistry, cell and molecular biology
3122 Cancers
Tekijänoikeustiedot:


Tiedostot

Latausmäärä yhteensä: Ladataan...

Tiedosto(t) Koko Formaatti Näytä
Holm_et_al_2019_FASEB_BioAdvances.pdf 463.0KB PDF Avaa tiedosto
Holm_et_al_2019_FASEB_BioAdvances.pdf 8.464MB PDF Avaa tiedosto

Viite kuuluu kokoelmiin:

Näytä kaikki kuvailutiedot